A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
Times cited: 14
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Journal of Clinical Oncology.
Times cited: 144